Research programme: phosphatase inhibitors - Amgen
Alternative Names: Research programme: WIP1 inhibitors - AmgenLatest Information Update: 09 Sep 2008
At a glance
- Originator Amgen
- Class Small molecules
- Mechanism of Action Phosphoric monoester hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Aug 2004 Tularik has been acquired and merged into Amgen
- 15 Aug 2003 Preclinical trials in Cancer in USA (unspecified route)
- 15 Jun 2000 Preclinical development for Breast cancer in USA (Unknown route)